Comparative Efficacy of Dupilumab, Tralokinumab, and Lebrikizumab on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A Frequentist Network Meta-Analysis

Ebglyss (lebrikizumab-lbkz) - Eli Lilly

Adbry (tralokinumab-ldrm) - LEO Pharma, AstraZeneca

Dupixent (dupilumab) - Sanofi, Regeneron

Marc Armengol-Gairí

Aug 6, 2026